Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have earned a consensus rating of “Buy” from the seven research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $54.20.

Several analysts have issued reports on TARS shares. William Blair upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. The Goldman Sachs Group upped their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, November 15th. Finally, Oppenheimer upped their price target on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Franklin Resources Inc. raised its stake in shares of Tarsus Pharmaceuticals by 9.3% during the third quarter. Franklin Resources Inc. now owns 12,164 shares of the company’s stock valued at $444,000 after acquiring an additional 1,033 shares during the last quarter. Alpha DNA Investment Management LLC raised its stake in Tarsus Pharmaceuticals by 9.1% in the second quarter. Alpha DNA Investment Management LLC now owns 15,174 shares of the company’s stock worth $412,000 after buying an additional 1,261 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock worth $166,000 after buying an additional 1,530 shares in the last quarter. Profund Advisors LLC raised its stake in Tarsus Pharmaceuticals by 26.8% in the second quarter. Profund Advisors LLC now owns 9,126 shares of the company’s stock worth $248,000 after buying an additional 1,929 shares in the last quarter. Finally, Quest Partners LLC bought a new position in Tarsus Pharmaceuticals in the second quarter worth about $61,000. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Stock Performance

NASDAQ TARS opened at $50.40 on Friday. The company has a 50-day simple moving average of $41.40 and a two-hundred day simple moving average of $33.42. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals has a 12-month low of $15.60 and a 12-month high of $52.99. The firm has a market cap of $1.93 billion, a price-to-earnings ratio of -13.23 and a beta of 1.04.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.